If you’ve heard about Zepbound® (tirzepatide) and are wondering whether Medicare will help pay for it in 2026, you’re not alone. Millions of older Americans struggle with obesity and its complications, including heart disease, sleep apnea, arthritis, high...
Over the past several years, GLP-1 medications have transformed the treatment of obesity and Type 2 diabetes. While many people recognize these medications for their ability to promote significant weight loss, researchers have discovered that their benefits extend far...
A Review of the Science Behind Medicare’s New Approach to Obesity Treatment and Cardiovascular Disease Prevention Beginning in July 2026, the Centers for Medicare & Medicaid Services (CMS) launched the Medicare GLP-1 Bridge Program, a temporary demonstration...
For many people, losing weight isn’t simply a matter of eating less and exercising more. Obesity is now recognized as a chronic medical condition influenced by genetics, hormones, metabolism, medications, stress, sleep, and lifestyle. Fortunately, advances in...
